Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Metastatic pancreatic cancer 2008: is the glass less empty?

Nieto J, Grossbard ML, Kozuch P.

Oncologist. 2008 May;13(5):562-76. doi: 10.1634/theoncologist.2007-0181. Review.

3.

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G.

Oncol Rep. 2010 May;23(5):1183-92. Review.

PMID:
20372829
5.

Treatment of metastatic pancreatic cancer.

Ko AH, Tempero MA.

J Natl Compr Canc Netw. 2005 Sep;3(5):627-36. Review.

PMID:
16194454
6.

[Gemcitabine and pancreatic cancer].

Prost P, Ychou M, Azria D.

Bull Cancer. 2002 Aug;89 Spec No:S91-5. Review. French.

PMID:
12449037
7.

Systemic treatment of pancreatic cancer.

Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C.

Eur J Gastroenterol Hepatol. 2004 Mar;16(3):265-74. Review.

PMID:
15195889
8.

Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.

Gounaris I, Zaki K, Corrie P.

JOP. 2010 Mar 5;11(2):113-23. Review.

9.

Gemcitabine in the treatment of metastatic pancreatic cancer.

Hilbig A, Oettle H.

Expert Rev Anticancer Ther. 2008 Apr;8(4):511-23. doi: 10.1586/14737140.8.4.511. Review.

PMID:
18402518
10.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
11.

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Ying JE, Zhu LM, Liu BX.

World J Gastroenterol. 2012 Feb 28;18(8):736-45. doi: 10.3748/wjg.v18.i8.736. Review.

12.
14.

Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy.

Wolff RA.

Cancer J. 2007 May-Jun;13(3):175-84. Review.

PMID:
17620767
15.

Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.

Brasiūnas V, Brasiūniene B, Juozaityte E, Barauskas G.

Medicina (Kaunas). 2004;40(11):1074-80.

16.

Advancements in the management of pancreatic cancer.

Li J, Saif MW.

JOP. 2009 Mar 9;10(2):109-17.

17.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
18.

[Adjuvant treatment of pancreatic cancer].

Oettle H.

Zentralbl Chir. 2003 May;128(5):411-8. Review. German.

PMID:
12813641
19.

Pancreatic cancer: the evolving role of systemic therapy.

Adsay NV, El-Rayes BF, Philip PA.

Expert Opin Pharmacother. 2001 Dec;2(12):1939-47. Review.

PMID:
11825326
20.

Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.

Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu JM, Oudard S.

Drugs Aging. 2007;24(10):865-79.

PMID:
17896834

Supplemental Content

Support Center